The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model.

[1]  A. Romano,et al.  Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. , 2004, American journal of ophthalmology.

[2]  J. Blondeau.  Fluoroquinolones: mechanism of action, classification, and development of resistance. , 2004, Survey of ophthalmology.

[3]  M. Chalita,et al.  Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. , 2004, American journal of ophthalmology.

[4]  E. Romanowski,et al.  Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. , 2003, American journal of ophthalmology.

[5]  E. Romanowski,et al.  Infectious disease: changing antibiotic susceptibility. , 2003, Ophthalmology clinics of North America.

[6]  D. Hooper.  Fluoroquinolone resistance among Gram-positive cocci. , 2002, The Lancet. Infectious diseases.

[7]  E. Romanowski,et al.  Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. , 2002, American journal of ophthalmology.

[8]  E. Romanowski,et al.  An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. , 2001, Ophthalmology.

[9]  D. Grasela.  Clinical pharmacology of gatifloxacin, a new fluoroquinolone. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. Baum,et al.  Emerging fluoroquinolone resistance in bacterial keratitis: A 5-year review , 1999 .

[11]  I. Constable,et al.  Implantation of PHEMA Keratoprostheses After Alkali Burns in Rabbit Eyes , 1998, Cornea.